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Abstract
Background: Research investments are essential to address the burden of disease, however allocation of limited resources is
poorly documented. We systematically reviewed the investments awarded by funding organisations to UK institutions and
their global partners for infectious disease research.
Methodology/Principal Findings: Public and philanthropic investments for the period 1997 to 2010 were included. We
categorised studies by infectious disease, cross-cutting theme, and by research and development value chain, reflecting the
type of science. We identified 6165 funded studies, with a total research investment of UK £2.6 billion. Public organisations
provided £1.4 billion (54.0%) of investments compared with £1.1 billion (42.4%) by philanthropic organisations. Global
health studies represented an investment of £928 million (35.7%). The Wellcome Trust was the leading investor with £688
million (26.5%), closely followed by the UK Medical Research Council (MRC) with £673 million (25.9%). Funding over time
was volatile, ranging from ,£40 million to ,£160 million per year for philanthropic organisations and ,£30 million to
,£230 million for public funders.
Conclusions/Significance: Infectious disease research funding requires global coordination and strategic long-term vision.
Our analysis demonstrates the diversity and inconsistent patterns in investment, with volatility in annual funding amounts
and limited investment for product development and clinical trials.
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Introduction
Since 2000, there has been substantial increase in international
financing for global health from donor governments and
innovative financing, in particular for infectious diseases.[1]
While the Organization for Economic Cooperation and
Development (OECD) tracks donor contributions to overseas
development assistance for health, including for selected infectious
diseases, there are no internationally adopted systems for tracking
innovative financing1 or investments in infectious disease research
for addressing global health burden, by countries, or by funding
entities. To date, few studies have analysed research and
development (R&D) investments.[2–3]
Annual global research and development (R&D) funding for
neglected diseases,[4] and funding by the National Institutes of
Health (NIH) of the United States (US) Department of Health and
Human Services have been estimated for selected years.[5–6] A
recent systematic analysis of infectious disease research invest-
ments in the United Kingdom (UK) from 1997 to 2010 and
burden of disease in 2004 and 2008 revealed mismatches between
the amounts of funds invested and the burden of disease caused by
the conditions, raising concerns about the efficiency of allocation
of the investments in infectious disease R&D.[2,7]
The World Health Organization (WHO) Consultative Expert
Working Group on Research and Development: Financing and
Coordination is currently reviewing the feasibility of establishing a
global observatory to monitor R&D investments.[8–11] The
initiative was endorsed by member states at the sixty-sixth World
Health Assembly this year.
We present the first systematic and comprehensive analysis of
investments in infectious disease R&D over the 14-year period
from 1997 to 2010. Specifically, the analysis focuses on investment
patterns by global health institutions funding infectious disease
research.
Methods
We obtained data from several sources for infectious disease
research studies where funding was awarded between 1997 and
2010 (full list and further resources on methodology are openly
available from http://researchinvestments.org/data). Figure 1
shows the sources of data and the numbers of studies explored
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at each stage of screening to reach the final set of studies for
detailed analysis. We identified 6165 relevant studies for analysis.
We assigned each study to primary disease categories. We outline
the methodology for the categorisation of disease areas and
classification of the funding sources, elaborated in detail previous-
ly.[2]
The overarching dataset was constructed by collating open-
access data and directly contacting the major sources of public and
philanthropic funding for infectious disease research studies,
including the Wellcome Trust, Medical Research Council and
other research councils, UK government departments, the
European Commission, Bill and Melinda Gates Foundation, and
Figure 1. Sources and numbers of studies screened. BBSRC= Biotechnology and Biological Sciences Research Council. ESRC= Economic and
Social Research Council. R&D=Research and Development. Total number of studies differs by n = 5 (0.08%) from previously published work following
ongoing review of the data by the study team [2].
doi:10.1371/journal.pone.0105722.g001
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other research charities. We also searched other databases,
including Clinicaltrials.gov and the National Research Register.
Within each category, we documented topic-specific subsections,
including specific pathogen or disease. We allocated studies to one
of four categories along the R&D continuum: pre-clinical; phases
I, II or III; product development; and operational research (which
includes epidemiological and implementation research). We
developed nine major categories for funding organisations, based
on total levels of research investment, and cross-referenced grants
from funding organisation to disease categories and stage of R&D
funding.
Global health studies include investments to UK institutions
with a global partner organisation, or studies predominantly
carried out or focused on a country other than the UK.
Antimicrobial resistance includes antibacterial, antiviral, antifun-
gal and antiparasitic studies. Reference to sexually transmitted
infections excludes HIV/AIDS. Neglected tropical diseases
(NTDs) were categorised based on the infections focused on by
WHO (for the list of NTDs focused on by WHO see http://www.
who.int/neglected_diseases/diseases/en). No private sector fund-
ing was included in this analysis as open-access data were limited.
Grants awarded in a currency other than pounds sterling were
converted to UK pounds using the mean exchange rate in the year
of the award (http://www.oanda.com/currency/average). All
grant funding amounts were adjusted for inflation and reported
in 2010 UK pounds.
We excluded studies not immediately relevant to infection,
veterinary infectious disease research studies (unless there was a
zoonotic component) those exploring the use of viral vectors to
investigate non-communicable diseases, grants for symposia or
meetings, or studies with UK contributions (e.g. as a collaborator),
but the funding was awarded to a non-UK institution. Unfunded
studies were excluded.
We used Microsoft Excel (versions 2000 and 2007) to categorize
studies. Where needed, data were exported into Microsoft Access
(versions 2000 and 2007) and specific keyword queries used to
select precise sections of the data for analysis. We used Stata
(version 11.0; StataCorp LP, Texas) for statistical analysis and to
generate figures.
We then systematically analysed the investments by major
funding organisations for research projects where a UK institution
acted as a leading partner. For multi-centre collaborative studies,
we included data where apportioned funding was indicated where
UK institutions were the leading partner. For multi-centre
collaborative studies where a UK institution was not a leading
partner, we were unable to include the funding, which may
represent an underestimate (particularly for studies led in the
European Union or the United States). We used fold differences to
Figure 2. Investment in immunology and vaccine research by funding organisation. BBSRC=Biotechnology and Biological Sciences
Research Council. DH=Department of Health. MRC=Medical Research Council. Blue designates philanthropic funding organisations. Red designates
public funding organisations. Yellow designates other funding organisations.
doi:10.1371/journal.pone.0105722.g002
Funding Infectious Disease Research
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e105722
Funding Infectious Disease Research
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e105722
measure the quantity of change in total investment, number of
studies, mean grant, and median grant according to disease
system, specific infection and funding organisation. We present
median grants in the results section to minimize the effect of the
skew from few, very large international project awards led by a
UK institution.
We used nonparametric Mann-Whitney rank-sum test to assess
the distribution of funding by funding source. Nonparametric K-
sample test on equality of medians was applied to compare the
median funding by funding source, and reported as a chi-squared
statistic without Yates’ correction for continuity. Nonparametric
Wilcoxon signed-rank test was applied when comparing matched
data, such as time trends by funding source. The significance for
all tests was defined at the 5% level (two-sided P=0.05).
Results
We identified 6165 funded studies in infectious disease research
with total research investment of UK £2.6 billion. Of these, 2385
studies (38.7%) were investments by public research funding
organisations totalling £1.4 billion (54%), 2874 studies (46.6%) by
philanthropic funding organisations totalling £1.1 billion (42.4%).
Global health studies represented an investment of £928 million
(35.7%). Overall, the mean amount of grant funding awarded was
£421 733 (SD £1 315 935) and the median amount of grant
funding awarded was £158 055 (IQR £49 490 – £352 699).
Figure 2 shows the overall ranking of funding organisations by
total research investment. The Wellcome Trust was the leading
investor in infectious disease research with £688 million (26.5%),
closely followed by the UK Medical Research Council (MRC)
with £673 million (25.9%). Major funding organisations included
the European Commission with £255 million (9.8%), the Bill and
Melinda Gates Foundation with £220 million (8.5%) and the
Biotechnology and Biological Sciences Research Council (BBSRC)
with £186 million (7.2%). Charities and smaller foundations
collectively accounted for £193 million of investment (7.4%)
across 851 studies (13.8%).
Figure 3 shows the trends in research funding according to
funding organisation over time. The Bill and Melinda Gates
Foundation awarded the largest mean and median amount of
grant funding at £5 664 699 (SD £8 966 093) and £1 488 432
(IQR £628 545 – £5 576 863), respectively.
Figure 4 compares the total investment and median amount of
grant funding awarded by public and philanthropic investors. The
public funding has been larger in 11 of the 14 years studied than
philanthropic organisations, which accounts for a significant
proportion of the funding ranging from 38% to 72% of total
annual funding. Funding is volatile ranging, from ,£40 million to
,£160 million for the philanthropic organisations and ,£30
million to ,£230 million for the public funders. There is no
obvious trend suggesting that the annual funding is increasing and
has been fairly flat since 2005. The average median funding
awarded by public organisations is larger at £255 992 (IQR £127
167 – £529 610), compared with £146 060 (IQR £52 433 – £286
518) for philanthropic organisation, almost two fold difference.
Figure 5 shows an overall increase in research funding, greatest for
public funding organisations. However the levels of funding are
volatile over time, and the linear regression best-fit line should be
interpreted with caution.
Funding along the research and development stages
Table 1 shows investment by funding source and research and
development (R&D) stages. The funding for preclinical research
accounted for the majority of investment with £1.6 billion (62.4%)
with a median grant of £193 149 (IQR £74 157 – £365 587).
Public investors funded 57.5% of the research with philanthropic
investors funding 40.5%.
Phase I, II, III clinical trials accounted for £147 million (5.6%)
with the highest median grants at £213 471 (IQR £53 116 – £839
713). Public investors funded 73.4% of the research with
philanthropic investors funding 18.7%. Industry funding, a major
source of investment in clinical trials, could not be accurately
sourced and was excluded from this analysis. Operational research
accounted for £697 million (26.8%) with the lowest median grants
at £88 232 (£18 513 – £250 423). Philanthropic investors funded
52.7% of the research with public investors funding 42.0%.
Trends in investment over time by R&D pipeline is highlighted in
figures S1 and S2.
Product development research accounted for the least invest-
ment with £133 million (5.1%) with a median grant of £147 621
(IQR £38 625 – £409 663). Public investors funded 52.0% of the
research with philanthropic investors funding 38.0%.
Table 2 shows the ranking of funding organisation according to
research type. The type of science funded by different organisa-
tions clearly varies according to the priorities of each funding
organisation. The Wellcome Trust, MRC, European Commission,
and BBSRC concentrated their investment on preclinical research
(70.6%, 78.4%, 73.6% and 100%, respectively). The Bill and
Melinda Gates Foundation, Department of Health and other UK
government sources concentrated their research investment on
operational research (77.2%, 69.2% and 44.9%, respectively).
Infectious disease system
Table S1 shows investment by infectious disease system, and
specific infection.
The total funding for HIV-related research projects was the
greatest with £478 million (18.4%) followed by respiratory
infections with £419 million (16.1%), haematological infections
with £413 million (15.9%). Gastrointestinal infections received
£249 million (9.6%) and NTDs received £230 million (8.8%).
Public investors accounted for the majority of research funding for
HIV, gastrointestinal, hepatic, respiratory, and sexually transmit-
ted infections. In contrast, philanthropic investors accounted for
the majority of research funding for NTDs, haematological
infections (primarily malaria) and ophthalmic infections. Largest
mean grants were awarded to HIV at £625 073 (SD £2 276 762),
with grants by public investors 2.46 fold greater than philanthropic
investors. Largest median grants were awarded to NTDs at £248
750 (IQR £91 196–£451 453), with grants by public investors
1.75 fold greater than philanthropic investors.
Specific infection
Several infections are highly supported by public funding
sources compared with philanthropic support. Notable examples
include influenza with a 6.38 fold difference (£67.8 million versus
£10.6 million), chlamydia with a 9.02 fold difference (£17.7
million versus £2.0 million), campylobacter with a 32.87 fold
difference (£22.8 million versus £0.7 million), and salmonella with
a 4.39 fold difference (£45.0 million versus £10.2 million).
Figure 3. Trends in investment over time: a) stratified by funding organisation, b) stratified by public versus philanthropic funder.
BBSRC=Biotechnology and Biological Sciences Research Council. DH=Department of Health. MRC=Medical Research Council.
doi:10.1371/journal.pone.0105722.g003
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Conversely, philanthropic funding sources greatly outweigh public
funding for African Trypanosomiasis (£36.0 million versus £6.7
million), lymphatic filariasis (£45.2 million versus £1.8 million),
schistosomiasis (£36.3 million versus £4.4 million), meningitis
(£35.3 million versus £16.3 million) and EBV (£32.3 million
versus £12.1 million).
Cross-cutting theme
Novel technologies to fight infection played an important role in
infectious disease research funding. Diagnostics research account-
ed for £100 million of investment (3.9%), primarily by the
Department of Health (23.4%), Cancer Research UK (17.0%) and
the European Commission (11.5%). Therapeutics research
accounted for £408 million (15.7%), primarily by the European
Commission (22.6%), Bill and Melinda Gates Foundation (18.4%)
and the Wellcome Trust (16.5%). Vaccine research accounted for
£235 million (9.0%), with major funders being the MRC (25.6%),
Wellcome Trust (21.4%) and the European Commission (18.3%).
Trends in investment over time by technologies to tackle infectious
diseases are highlighted in figures S1 and S2. According to type of
microbiological organism, viruses were the major area of funding
with £1.0 billion (39.5%) followed by parasites with £667 million
(25.7%), and bacteria with £588 million (22.6%). Fungal research
attracted £48 million (1.9%) and prion research attracted £34
million (1.3%), primarily from the Department of Health. All
microbiological categories were funded primarily by public
investors, with exception of parasitology where 67.1% of funding
came from philanthropic investors.
Discussion
We present the first study to systematically analyse the
investment by funding organisations for infectious disease
research. Funding trends over time highlight the disparities in
funding amounts and stage of funding between funding organi-
sations and the infectious diseases they fund. Studies with a clear
global health focus, i.e. those performed outside of the UK, in
partnership with an international collaborator, or studying a
disease primarily affecting a low-income setting, represented
35.7% of total investment (£928 million).
Figure 5. Fitted trend in investment by public versus philanthropic funder over time. Full line represents annual expenditure. Dotted line
represents linear regression best-fit line over the 14-year study period.
doi:10.1371/journal.pone.0105722.g005
Figure 4. Trends in investment by public versus philanthropic funder over time: a) total research investment, b) median research
investment.
doi:10.1371/journal.pone.0105722.g004
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Table 2. Ranking of investment in immunology and vaccine research by a) disease system, b) cross-cutting theme, and c) specific
infectious disease.
Disease system Top funder 1 Top funder 2 Top funder 3 Top funder 4 Top funder 5
Gastrointestinal
infections
BBSRC Wellcome Trust MRC European Commission UK Government, non-DH
33.1% 31.3% 13.4% 8.8% 4.7%
Haematological
infections
Wellcome Trust Bill & Melinda Gates
Foundation
MRC European Commission Other funding
34.2% 29.9% 18.4% 6.7% 10.9%
Hepatic infections MRC Wellcome Trust DH European Commission BBSRC
33.4% 19.0% 12.5% 11.7% 4.6%
Neglected tropical
diseases
Wellcome Trust Bill & Melinda Gates
Foundation
MRC European Commission BBSRC
45.2% 29.3% 14.8% 9.1% 3.8%
Neurological infections DH Wellcome Trust MRC Meningitis Research
Foundation
Bill & Melinda Gates
Foundation
25.3% 24.9% 14.9% 12.1% 3.6%
Ocular infections Wellcome Trust MRC Charity UK Government, non-DH DH
63.3% 11.9% 7.4% 6.7% 6.4%
Respiratory infections Wellcome Trust MRC European Commission BBSRC Department for
International Development
32.3% 29.6% 8.0% 6.2% 3.3%
Sexually-transmitted
infections
MRC DH Cancer Research UK Department for
International Development
Wellcome Trust
29.5% 19.8% 19.1% 9.1% 6.5%
HIV MRC Department for
International Development
Wellcome Trust European Commission Bill & Melinda Gates
Foundation
33.8% 16.6% 15.8% 13.5% 7.5%
Overall Wellcome Trust MRC European Commission Bill & Melinda Gates
Foundation
BBSRC
26.47% 25.88% 9.81% 8.50% 7.16%
Disease system Top funder 1 Top funder 2 Top funder 3 Top funder 4 Top funder 5
Diagnostics DH Cancer Research UK European Commission UK Government, non-DH Wellcome Trust
23.4% 17.0% 11.5% 11.2% 10.7%
Therapeutics European Commission Bill & Melinda Gates
Foundation
Wellcome Trust MRC Department for
International Development
22.6% 18.5% 16.5% 16.0% 14.1%
Vaccines MRC Wellcome Trust European Commission Bill & Melinda Gates
Foundation
BBSRC
25.6% 21.4% 18.3% 12.2% 6.8%
Bacteriology Wellcome Trust MRC BBSRC European Commission DH
29.9% 21.8% 17.7% 8.2% 6.3%
Mycology BBSRC Wellcome Trust MRC European Commission National Institute for Health
30.5% 24.7% 16.6% 13.2% 6.2%
Parasitology Wellcome Trust Bill & Melinda Gates
Foundation
MRC European Commission BBSRC
41.2% 25.3% 15.2% 12.4% 2.8%
Prion DH European Commission UK Government, non-DH MRC Other funding
65.3% 11.3% 9.7% 6.2% 7.6%
Virology MRC Wellcome Trust Cancer Research UK European Commission Department for
International Development
35.1% 18.1% 10.5% 8.7% 6.9%
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Table 2. Cont.
Disease system Top funder 1 Top funder 2 Top funder 3 Top funder 4 Top funder 5
Overall Wellcome Trust MRC European Commission Bill & Melinda Gates
Foundation
BBSRC
26.47% 25.88% 9.81% 8.50% 7.16%
Specific infection Top funder 1 Top funder 2 Top funder 3 Top funder 4 Top funder 5
African
trypanosomiasis
Wellcome Trust MRC Bill & Melinda Gates
Foundation
European Commission WHO
75.4% 15.3% 8.8% 0.3% 0.1%
Aspergillus National Institute
for Health Research
Wellcome Trust Fungal Research Trust MRC Other funding
42.8% 35.4% 13.4% 7.4% 1.0%
Campylobacter BBSRC MRC UK Government, non-DH Wellcome Trust Other funding
82.2% 6.5% 6.1% 2.7% 2.5%
Candida National Institute
for Health Research
Fungal Research Trust Dunhill Medical Trust
88.0% 9.2% 2.7%
Chagas disease Wellcome Trust MRC European Commission
57.3% 23.5% 19.2%
Chlamydia Department of Health UK Government, non-DH MRC Wellcome Trust BUPA Foundation
49.9% 15.9% 13.5% 7.9% 4.0%
Clostridium BBSRC European Commission Wellcome Trust MRC National Institute for Health
Research
24.3% 20.3% 19.5% 17.1% 12.6%
CMV MRC Wellcome Trust NHS Bill & Melinda Gates
Foundation
National Institute for Health
65.5% 24.7% 5.6% 1.3% 0.8%
Dengue Bill & Melinda Gates
Foundation
Wellcome Trust MRC European Commission BBSRC
76.6% 12.5% 7.6% 2.6% 0.8%
Diphtheria European Commission UK Government, non-DH
84.5% 15.5%
E. coli BBSRC Wellcome Trust MRC Economic and Social
Research Council
European Commission
40.9% 39.0% 5.8% 5.1% 3.8%
EBV Cancer Research UK MRC Wellcome Trust BBSRC Other funding
55.9% 25.7% 14.7% 0.9% 2.7%
Gonorrhoea Wellcome Trust BBSRC UK Government, non-DH NHS Other funding
48.9% 25.6% 15.5% 4.4% 5.6%
Helicobacter MRC Cancer Research UK Wellcome Trust NHS Other funding
33.6% 28.8% 12.2% 5.7% 19.8%
Helminths Wellcome Trust Bill & Melinda Gates
Foundation
MRC BBSRC European Commission
53.7% 20.0% 14.0% 7.3% 4.5%
Hepatitis B MRC Wellcome Trust European Commission National Blood Service Department of Health
43.0% 23.3% 7.2% 4.4% 3.6%
Hepatitis C MRC Wellcome Trust DH European Commission UK Government, non-DH
35.1% 17.1% 14.3% 12.8% 4.5%
HIV MRC Department for
International Development
Wellcome Trust European Commission Bill & Melinda Gates
Foundation
33.8% 16.6% 15.8% 13.5% 7.5%
HPV Cancer Research UK MRC DH European Commission Wellcome Trust
50.8% 24.4% 9.2% 4.9% 3.4%
HSV MRC Wellcome Trust UK Government, non-DH BBSRC Other funding
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Table 2. Cont.
Specific infection Top funder 1 Top funder 2 Top funder 3 Top funder 4 Top funder 5
65.8% 23.7% 5.4% 3.2% 2.1%
Influenza MRC BBSRC European Commission Wellcome Trust Other funding
52.9% 16.6% 12.9% 12.7% 4.9%
Leishmaniasis Wellcome Trust European Commission MRC BBSRC
42.5% 35.3% 18.2% 4.0%
Leprosy Wellcome Trust
100.0%
Listeriosis BBSRC Wellcome Trust European Commission MRC
40.6% 26.2% 21.7% 11.6%
Lymphatic filariasis Bill & Melinda Gates
Foundation
MRC Wellcome Trust
95.5% 3.9% 0.6%
Malaria Wellcome Trust Bill & Melinda Gates
Foundation
MRC European Commission UK Government, non-DH
34.5% 26.1% 19.1% 13.0% 3.9%
Measles MRC European Commission UK Government, non-DH DH Wellcome Trust
49.2% 35.5% 7.3% 5.3% 2.7%
Meningitis Wellcome Trust Meningitis Research
Foundation
MRC DH Meningitis UK
27.4% 22.3% 21.2% 7.3% 4.4%
Norovirus Wellcome Trust European Commission MRC DH
47.7% 40.6% 9.9% 1.8%
Onchocerciasis European Commission Wellcome Trust
75.5% 24.5%
Pertussis Wellcome Trust UK Government, non-DH MRC Other funding
46.8% 31.0% 19.5% 2.8%
Polio MRC UK Government, non-DH
98.5% 1.5%
Pseudomonas MRC BBSRC Wellcome Trust DH UK Government, non-DH
33.2% 27.6% 10.8% 7.4% 6.9%
Rotavirus Wellcome Trust European Commission BBSRC MRC Other funding
57.9% 20.7% 11.2% 6.1% 4.1%
RSV Wellcome Trust MRC BBSRC UK Government, non-DH Other funding
44.8% 38.5% 5.3% 5.2% 6.3%
Salmonella BBSRC Wellcome Trust MRC European Commission Other funding
55.0% 18.4% 17.8% 8.1% 0.7%
Schistosomiasis Bill & Melinda Gates
Foundation
Wellcome Trust European Commission BBSRC Other funding
66.2% 22.9% 8.8% 1.3% 0.8%
Shigella Wellcome Trust European Commission MRC National Institute for Health
41.7% 25.3% 20.0% 13.1%
Syphilis Wellcome Trust MRC DH Terence Higgins Trust
53.5% 21.7% 19.5% 5.3%
Tetanus European Commission Wellcome Trust
83.6% 16.5%
Trachoma MRC
100.0%
Tuberculosis Wellcome Trust MRC Department for
International Development
European Commission Bill & Melinda Gates
Foundation
40.3% 23.2% 8.9% 7.8% 6.3%
VZV MRC DH Wellcome Trust Other funding
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Funding trends over time show that charitable funding declines
dramatically from 2007, suggesting that the financial crisis adversely
impact on health research funding, in particular from smaller
charities that were affected by the economic crisis. The volatility of
charitable funding is evident, both as a proportion of total
investment as well as the sum of total investment. In contrast,
funding for infectious disease research was stable, as a proportion of
funding and as total investment, for the large funding organisations
such as the Wellcome Trust and MRC. The funding landscape also
appears to be shifting. These data highlight the dependence on these
two leading funders for health research. In addition, the Bill and
Melinda Gates Foundation contribute substantially to infectious
disease research funding, interjecting a small number of grants of
great monetary value. The European Commission emerges as a
major funder, particularly from the year 2000.
Contrasting public and philanthropic funding, total investment
is consistently greater from public sources, both in terms of total
investment and median investment. Analysing these data over
time, the funding from public and philanthropic sources does not
appear to be equalising. Fitted values (figure 5) for public and
philanthropic funding do show a trend towards increased
financing for research overall. However, a drop in philanthropic
funding, attributed to the smaller charitable organisations, is
clearly apparent from 2007. It will be important to follow up
research investments over the coming years to see whether these
trends have reverted.
Of note, there is a lack of industry funding from the data. This is
primarily due to the methodological decision to exclude industry
funding from the analysis, as the open access data available on
R&D investments of pharmaceutical firms clearly underestimated
the contribution of industry to infectious disease research. Industry
partners are likely to contribute more towards clinical trials such as
phase 1, phase 2, and phase 3 studies. In order to make evidence-
informed decisions, we require complete and accurate data. The
pharmaceutical industry should work alongside public and
philanthropic funders in order to map, monitor, and evaluate
research funding. Publishing such data online in an open access
database, such as on www.researchinvestments.org, will be
mutually beneficial to both academic institutions and pharmaceu-
tical and biotech companies. In addition, it is unlikely that
divulging past and current research investments would jeopardise
research in progress. On the contrary, understanding the emerging
horizons in current research would allow complementary studies
to be performed, and the development of the research base.
We currently lack informative data on the distribution of studies
along the research and development pipeline.[10,12] Data from
this analysis shows the weight of preclinical research on funding.
The great majority of funding is allocated to preclinical work, with
a new minority allocated to phase 1, 2, 3 trials and product
development. Operational research, which includes epidemiolog-
ical studies, attracted the second greatest level of funding. This is
particularly strong in global health studies.[13–14] This trend does
not appear to change drastically over time.
We require innovative health financing, and new funding
streams to promote innovative delivery of new tools to fight
infectious diseases and address the burden of disease.[15–18]
Funding allocated for tools to tackle infectious diseases on the
other hand is more volatile. There is a clear surge in investment
from 2000. This investment wanes slightly over the years until
further boosts are made from the year 2005. Most of the
investment is allocated to therapeutics or studies involving drugs.
Vaccine research receives considerable investment, however this
tends to be concentrated according to intermittent funding
streams.[19] Diagnostics research appears to be the least well
funded of the tools for infectious disease control.
This study maps the research funding landscape for infectious
disease research in the UK. The UK is the second greatest funder
for global health, after the US.[20–21] It is essential that we
understand the funding contributions from other countries, both
from the major world economies of the G20 as well as the
investments made by local governments and NGOs in low-income
settings.[22] An example of a national system that promotes
transparency is the extensive online database on the ‘‘Research
Portfolio Online Reporting Tools’’ (RePORT) website by the NIH
Research, Condition, and Disease Categorization system (http://
report.nih.gov/catego rical_spending.aspx). In addition to a lack
of openness with industry funding, there is a lack of openness for
large grants awarded to international consortia. In the case of
these consortia, although the total grant is often well documented,
the international transactions between the lead institution and
partner institutions are less well documented.
This work has major implications for academic institutions,
governments, funding organisations, and policy makers. Particu-
larly with regards to public funding, there is a duty to invest scarce
resources wisely.[23] However, if governments, policy-makers and
executives of the funding organisations are allocating resources
without accurate knowledge of the current funding terrain, there is
bound to be inefficiency.
We urge funding organisations to share data online so that
trends in funding may be appropriately assessed. RESIN: Research
Investments in Global Health (www.researchinvestments.org) is an
initiative that aims to act as an open access portal to facilitate
documentation of investments in health research. Inequities in
research funding have major implications for global health. Simple
measures such as documentation and dissemination of data may act
to redress these inequities.
Supporting Information
Figure S1 Trends in investment over time: a) stratified by research
and development phase, b) stratified by infectious disease tool.
(JPG)
Table 2. Cont.
Specific infection Top funder 1 Top funder 2 Top funder 3 Top funder 4 Top funder 5
45.9% 22.5% 15.5% 16.1%
Overall Wellcome Trust MRC European Commission Bill & Melinda Gates
Foundation
BBSRC
26.47% 25.88% 9.81% 8.50% 7.16%
BBSRC =Biotechnology and Biological Sciences Research Council. DH =Department of Health. MRC=Medical Research Council. CMV=Cytomegalovirus. EBV = Epstein-
Barr virus. HIV =Human immunodeficiency virus. HPV =Human Papillomavirus. HSV =Herpes Simplex virus. RSV = Respiratory Syncytial virus. VZV = Varicella Zoster virus.
doi:10.1371/journal.pone.0105722.t002
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Figure S2 Proportion of investment over time: a) stratified by
research and development phase, b) stratified by infectious disease
tool.
(JPG)
Table S1 Investment in immunology and vaccine research by a)
specific infectious disease and b) disease system. CMV=Cytome-
galovirus. EBV=Epstein-Barr virus. HIV=Human immunodefi-
ciency virus. HPV=Human Papillomavirus. HSV=Herpes
Simplex virus. RSV=Respiratory Syncytial virus. VZV=Var-
icella Zoster virus.
(XLS)
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